Novo Nordisk® py trial and phase 1 combination d weight by 10.8% and 17.1% Weight loss for AM833 and semaglutide in phase 12 % change in body weight 0 -2 -4 -6 --88 -10 --1122 -14 -16 -18 -220 0 0 AM833 0.3 mg sema 2.4 mg sema 2.4 mg Mean baseline: 95.1 kg - 9.5% - 17.1% 4 8 AM833 0.16 mg sema 2.4 mg 12 WWeeeekkss AM833 0.6 mg sema 2.4 mg 16 AM833 1.2 mg sema 2.4 mg 20 20 AM833 2.4 mg sema 2.4 mg product estimand: treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies ose-escalation regimen. Data is based on the trial product estimand.
Download PDF file